TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/04/2025
Voltar para busca
Dado oficial do USPTO
T-CEPTOR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
T-CEPTOR
ST13
US500000098081098Classe
5, 42, 44
Pedido
98081098
Registro
7683956
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
03/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
12/07/2023
Data de registro
11/02/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/02/2025
Última transação
03/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Cambridge, GB
Examinador
ANDERSON, DANIELLE
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
T-Therapeutics Limited
Representantes
Stacy J. Grossman SGIP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposesfor protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposespharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; immunotherapeutic drugs namelypharmaceutical preparations for protection from and prevention of viral and bacterial infectionscancerinflammationinfectious diseases and non-infectious diseasesmusculoskeletalcardiovascularcardiopulmonaryoncologicalneurologicaldermatologicalgenitourinarysexual dysfunctionhepatologicalophthalmicrespiratorygastrointestinalhormonalpsychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes
Classe 42
Scientific and technological servicesscientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infectionscancerdisease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticalsbiopharmaceutical drug development and genome engineering for protection and prevention from infectionscancerdisease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals
Classe 44
Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNAgeneticsgenetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
28/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/04/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/02/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/12/2024
PUBO
PUBLISHED FOR OPPOSITION
24/12/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/12/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/11/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
22/11/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/11/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
22/11/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/11/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/11/2024
GNFR
FINAL REFUSAL E-MAILED
13/11/2024
CNFR
FINAL REFUSAL WRITTEN
13/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/10/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/10/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/10/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/07/2024
GNRT
NON-FINAL ACTION E-MAILED
10/07/2024
CNRT
NON-FINAL ACTION WRITTEN
10/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/06/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
31/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
31/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
31/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/03/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/03/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/03/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/03/2024
GNRT
NON-FINAL ACTION E-MAILED
23/03/2024
CNRT
NON-FINAL ACTION WRITTEN
23/03/2024
DOCK
ASSIGNED TO EXAMINER
20/03/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/08/2023
NWAP
NEW APPLICATION ENTERED
15/07/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace T-CEPTOR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.